# US 2021/0275462 A1 · Nanoparticulate prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275462 A1
- Document ID: US20210275462A1
- Status: Published application
- Kind: A1
- Application number: 16/334,598
- Filed: 2017-09-20
- Published: 2021-09-09
- Earliest claimed: 2016-09-20
- Assignees: Centre National De La Recherche Scientifique; Universite Paris-Sud 11
- Applicants: Centre National De La Recherche Scientifique; Université Paris-Sud 11
- Inventors: Elias FATTAL; Nicolas TSAPIS; Mathilde LORSCHEIDER; Romain CANIONI; Franceline REYNAUD
- Web page: https://patentgrep.com/patent/US20210275462A1

## CPC

- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5192: {Processes}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed is an anti-inflammatory drug formulation, especially a corticosteroid prodrug nanoparticle. In a first aspect, a nanoparticle includes a therapeutic agent and a surface coating material. Also disclosed are a process of manufacturing at least one nanoparticle, a pharmaceutical composition, and pharmaceutical kits.

## Claims

### Claim 1

Nanoparticle comprising a glucocorticoid prodrug and a surface coating material wherein the nanoparticle size is ranging from 20 to 400 nm; wherein the glucocorticoid prodrug is a lipophilic long-chain ester of a glucocorticoid; wherein the glucocorticoid prodrug is in an amorphous state; and wherein the glucocorticoid prodrug loading rate is higher than 10% in weight to the weight of nanoparticle.

### Claim 2 (depends on 1)

The nanoparticle according to claim 1, wherein the glucocorticoid prodrug is a lipophilic long-chain ester of dexamethasone.

### Claim 3 (depends on 1)

The nanoparticle according claim 1, wherein the glucocorticoid prodrug is dexamethasone palmitate.

### Claim 4 (depends on 1)

The nanoparticle according to claim 1, wherein the surface coating material is selected from poloxamer 407, poloxamer 188, polyoxyethylene (40) monostearate, polysorbate 20, polysorbate 80, tyloxapol, polyoxyl (40) hydrogenated castor oil, Polyoxyl (35) hydrogenated castor oil, Tocopherol polyethylene glycol succinate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt) and polyvinyl alcohol.

### Claim 5 (depends on 1)

The nanoparticle according to claim 1, wherein the surface coating material is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt).

### Claim 6 (depends on 1)

The nanoparticle according claim 1, wherein the nanoparticle has a polyoxyethylene surface density, as defined in Test A, smaller than 0.30 nm2 per polyoxyethylene chain.

### Claim 7 (depends on 1)

Medicament comprising at least one nanoparticle according to claim 1.

### Claim 8 (depends on 1)

Pharmaceutical composition comprising at least one nanoparticle according to claim 1 and at least one pharmaceutically acceptable excipient.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is formulated for intravenous administration.

### Claim 10 (depends on 1)

The nanoparticle according to claim 1 for use in the treatment of inflammatory diseases or conditions.

### Claim 11 (depends on 10)

The nanoparticle for use according to claim 10, wherein the inflammatory disease is selected from rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and lupus erythematous.

### Claim 12 (depends on 8)

Kit comprising a container containing a pharmaceutical composition according to claim 8.

### Claim 13 (depends on 1)

Process for manufacturing at least one nanoparticle according to claim 1, wherein the process for manufacturing is a nanoprecipitation process or an emulsion-evaporation process, starting from a solution of glucocorticoid prodrug and surface coating material in volatile solvent and aqueous solution, or from a solution of glucocorticoid prodrug in volatile solvent and a aqueous solution of surface coating material.

### Claim 14 (depends on 13)

The process of claim 13, wherein the process starts from a solution of glucocorticoid prodrug and surface coating material in volatile solvent and water.

### Claim 15 (depends on 13)

The process of claim 13, wherein the process starts from a solution of glucocorticoid prodrug in volatile solvent and a water solution of surface coating material.

### Claim 16 (depends on 2)

The nanoparticle according claim 2, wherein the glucocorticoid prodrug is dexamethasone palmitate.

### Claim 17 (depends on 2)

The nanoparticle according to claim 2, wherein the surface coating material is selected from poloxamer 407, poloxamer 188, polyoxyethylene (40) monostearate, polysorbate 20, polysorbate 80, tyloxapol, polyoxyl (40) hydrogenated castor oil, Polyoxyl (35) hydrogenated castor oil, Tocopherol polyethylene glycol succinate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt) and polyvinyl alcohol.

### Claim 18 (depends on 3)

The nanoparticle according to claim 3, wherein the surface coating material is selected from poloxamer 407, poloxamer 188, polyoxyethylene (40) monostearate, polysorbate 20, polysorbate 80, tyloxapol, polyoxyl (40) hydrogenated castor oil, Polyoxyl (35) hydrogenated castor oil, Tocopherol polyethylene glycol succinate, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt) and polyvinyl alcohol.

### Claim 19 (depends on 2)

The nanoparticle according to claim 2, wherein the surface coating material is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt).

### Claim 20 (depends on 3)

The nanoparticle according to claim 3, wherein the surface coating material is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000] (ammonium salt).
